Case report: Cytopenias in VEXAS syndrome - a WHO 2022 based approach in a single-center cohort

Case report: Cytopenias in VEXAS syndrome - a WHO 2022 based approach in a single-center cohort

VEXAS syndrome is an acquired autoinflammatory disease characterized in most cases by cytopenias and macrocytic anemia. Dyshematopoiesis is a frequent finding in chronic inflammatory conditions and therefore, cytopenias are not easily classified in VEXAS patients. Here we report a series of 7 patien...

Full description

Bibliographic Details
Main Authors:	Elisa Diral, Corrado Campochiaro, Alessandro Tomelleri, Gregorio M. Bergonzi, Umberto Pizzano, Maurilio Ponzoni, Lucia Bongiovanni, Paola Ronchi, Cristina Tresoldi, Silvia Rigamonti, Federico Scarfò, Gloria M. Latino, Emma Rinaldi, Massimo Bernardi, Lorenzo Dagna, Fabio Ciceri
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-01-01
Series:	Frontiers in Immunology
Subjects:	myelodysplastic neoplasms (MDS) VEXAS syndrome next generating sequencing azacytidine ruxolitinib vacuoles
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1354130/full

Similar Items

USAID Associated with Myeloid Neoplasm and VEXAS Syndrome: Two Differential Diagnoses of Suspected Adult Onset Still’s Disease in Elderly Patients
by: Marion Delplanque, et al.
Published: (2021-11-01)

Vexas syndrome: a new hematoinflammatory disease
by: Roberto Michael Blanco-Alvarez, et al.
Published: (2023-07-01)

VEXAS and Myelodysplastic Syndrome: An Interdisciplinary Challenge
by: Virginie Kreutzinger, et al.
Published: (2024-02-01)

VEXAS Syndrome—Review
by: Zhang Zhang, et al.
Published: (2023-09-01)

Clinical, Morphological and Clonal Progression of VEXAS Syndrome in the Context of Myelodysplasia Treated with Azacytidine
by: Marco Manzoni, et al.
Published: (2022-05-01)

Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic
by: Giulio Cavalli, et al.
Published: (2020-12-01)

Autoimmunity and Autoinflammation: Relapsing Polychondritis and VEXAS Syndrome Challenge
by: Anca Cardoneanu, et al.
Published: (2024-02-01)

Digital Track Map for the VEXA expert system
by: Adam Hlubuček
Published: (2022-05-01)

VEXAS Syndrome—Diagnostic Clues for the Dermatologist and Gaps in Our Current Understanding: A Narrative Review
by: Lowell T. Nicholson, et al.
Published: (2024-01-01)

Vasculitis associated with VEXAS syndrome: A literature review
by: Ryu Watanabe, et al.
Published: (2022-08-01)

VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder
by: Huijun Huang, et al.
Published: (2021-03-01)

Case report: Successful use of mepolizumab for immune checkpoint inhibitors–induced hypereosinophilic syndrome in two patients with solid malignancies
by: Chiara Lazzari, et al.
Published: (2023-01-01)

A case of VEXAS syndrome presenting with unusual bone marrow granulomas: a diagnostic dilemma
by: Khiem T. Vu, et al.
Published: (2023-07-01)

Marginal zone lymphoma: Diagnostic challenges among different entities
by: Lucia Bongiovanni, et al.
Published: (2018-06-01)

Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim–Chester Disease
by: Alessandro Tomelleri, et al.
Published: (2018-06-01)

Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease
by: Giulio Cavalli, et al.
Published: (2019-02-01)

Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease
by: Giulio Cavalli, et al.
Published: (2019-02-01)

Case Report: Coexistence of Multiple Myeloma and Auricular Chondritis in VEXAS Syndrome
by: Haruki Matsumoto, et al.
Published: (2022-06-01)

VEXAS Syndrome: A Novelty in MDS Landscape
by: Marie Templé, et al.
Published: (2022-06-01)

A novel XNA-based Luminex assay to detect UBA1 somatic mutations associated with VEXAS syndrome
by: Yunqing Ma, et al.
Published: (2024-03-01)

VEXAS Syndrome: A Call for Diagnostic Awareness Based on a Case Series of Seven Patients
by: Filipe R. Pinto, et al.
Published: (2023-04-01)

Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation
by: Emanuel Della-Torre, et al.
Published: (2021-04-01)

A case of VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) with decreased oxidative stress levels after oral prednisone and tocilizumab treatment
by: Nagie Tozaki, et al.
Published: (2022-12-01)

EZN-2208 treatment suppresses chronic lymphocytic leukaemia by interfering with environmental protection and increases response to fludarabine
by: Roberta Valsecchi, et al.
Published: (2020-05-01)

Successful treatment with fludarabine and cyclophosphamide in a VEXAS syndrome patient with associated myelodysplastic syndrome: a case report and systematic review
by: Polina Bellman, et al.
Published: (2024-04-01)

Case Report: Tocilizumab Treatment for VEXAS Syndrome With Relapsing Polychondritis: A Single-Center, 1-Year Longitudinal Observational Study In Japan
by: Yosuke Kunishita, et al.
Published: (2022-06-01)

Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome presenting as recurrent aseptic peritonitis in a patient receiving peritoneal dialysis: a case report
by: Natsuki Fukuda, et al.
Published: (2024-01-01)

Exome sequencing can misread high variant allele fraction of somatic variants in UBA1 as hemizygous in VEXAS syndrome: a case report
by: Matheus V. M. B. Wilke, et al.
Published: (2022-08-01)

Periostin expression in uninvolved skin as a potential biomarker for rapid cutaneous progression in systemic sclerosis patients: a preliminary explorative study
by: Giacomo De Luca, et al.
Published: (2024-01-01)

PB2004: CHRONIC MYELOMONOCYTIC LEUKEMIA AND CONCOMITANT MONOCLONAL GAMMOPATHY: A MULTICENTRE RETROSPECTIVE STUDY OF CLINICAL CHARACTERISTICS, PREVALENCE AND OUTCOME
by: Elisa Diral, et al.
Published: (2023-08-01)

P778: A CARTOGRAPHY OF UBA1 GENE TESTING, EPIDEMIOLOGY AND CLINICAL-GENOMIC CHARACTERISTICS: THE VEXAS ITALIAN EXPERIENCE
by: Carmelo Gurnari, et al.
Published: (2023-08-01)

MOLECULAR INTERNATIONAL PROGNOSTIC SCORING SYSTEM FOR MYELODYSPLASTIC SYNDROMES: A MONOCENTRIC EXPERIENCE
by: E. Diral, et al.
Published: (2024-01-01)

Steroid reduction‐resistant pulmonary involvement with Sweet's syndrome suspected of being vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic syndrome: A case report
by: Yuki Amakusa, et al.
Published: (2024-02-01)

Response letter to “Latent class analysis of 216 patients with adult-onset Still’s disease” by Sugiyama et al.
by: Marion Delplanque, et al.
Published: (2022-12-01)

Efficacy and safety of IL-6 inhibitors in patients with COVID-19 pneumonia: a systematic review and meta-analysis of multicentre, randomized trials
by: Alessandro Belletti, et al.
Published: (2021-10-01)

Progressive, edematous plaques, mild pancytopenia, and inflammation
by: Leigh A. Compton, MD, PhD, et al.
Published: (2023-12-01)

Impact of Geographic Location on Diagnosis and Initial Management of Takayasu Arteritis: A Tale of Two Cohorts from Italy and India
by: Durga Prasanna Misra, et al.
Published: (2022-12-01)

Polyarteritis Nodosa: Old Disease, New Etiologies
by: Louis Wolff, et al.
Published: (2023-11-01)

Improving Diagnosis and Clinical Management of Acquired Systemic Autoinflammatory Diseases
by: Al-Hakim A, et al.
Published: (2022-10-01)

An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years
by: Corrado Campochiaro, et al.
Published: (2021-06-01)